Patient-focused biopharmaceutical developer advancing potent, selective small-molecule modulators to address unmet needs in oncology and autoimmune diseases. Pipeline includes PAD4 inhibitors for autoimmune disorders; dual LSD1/HDAC6, small-molecule PD‑L1, and brain-penetrant PRMT5 inhibitors targeting cancer.